GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
21.90
-1.40 (-6.01%)
Oct 31, 2025, 4:00 PM EDT
GSK plc Revenue
GSK plc had revenue of 8.55B GBP in the quarter ending September 30, 2025, with 6.68% growth. This brings the company's revenue in the last twelve months to 32.17B, up 2.73% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
32.17B GBP
Revenue Growth
+2.73%
P/S Ratio
2.17
Revenue / Employee
468.69K GBP
Employees
68,629
Market Cap
94.01B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
GSK plc News
- 4 days ago - GSK Shares Surge 4.9% on Strong Q3 Earnings and Raised 2025 Outlook - GuruFocus
- 4 days ago - GSK plc (GSK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - GSK (GSK) Surges on Strong Q3 Results and Improved Outlook - GuruFocus
- 4 days ago - GSK boss: Britain must reform drug pricing to become a life sciences superpower - The Guardian
- 4 days ago - GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - Nasdaq
- 4 days ago - GSK Stock Rises as Strong Performance Boosts Outlook - GuruFocus
- 4 days ago - GSK Shares Leap 4% as Pharma Giant Boosts Guidance on Vaccine Breakthrough - ABC Money
- 4 days ago - GSK rises on higher profit growth projected for 2025 - Seeking Alpha